Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference60 articles.
1. The trials and tribulations of producing the first genetically engineered drug;Johnson;Nat Rev Drug Discov,2003
2. Scientific and legal viability of follow-on protein drugs;Dudzinski;N Engl J Med,2008
3. The challenge of follow-on biologics for treatment of multiple sclerosis;Reingold;Neurology,2009
4. Worldwide experience with biosimilar development;McCamish;MAbs,2011
5. Controlling the cost of innovative cancer therapeutics;Malik;Nat Rev Clin Oncol,2009
Cited by 58 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nanosimilars: A Scientific or A Regulatory Debate?;The AAPS Journal;2024-07-02
2. Obstacles to Biosimilar Acceptance and Uptake in Oncology;JAMA Oncology;2024-07-01
3. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review;Survey of Ophthalmology;2024-07
4. Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study;RMD Open;2024-02
5. Regulatory Considerations of Biosimilars in Cancer;Biosimilars for Cancer Treatment;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3